Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 2 October 2022
Accepted: 26 October 2022
First Online: 8 November 2022
Declarations
:
: N. Scherbaum has received honoraria for several activities (e.g., advisory board membership, lectures, manuscripts) from AbbVie, Camurus, Hexal, Janssen-Cilag, MSD, Medice, Mundipharma, Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last three years he has participated in clinical trials financed by the pharmaceutical industry. M. Specka, P. Roser & U. Bonnet have no conflicts of interest to declare.